eli lilly glp 1 Lilly's Obesity Pill Appears to Work as Well as Injected GLP-1s LLY Stock Outlook: Employer Connect

Cagrilintide is a long-acting amylin analog that suppresses appetite through a pathway completely independent of GLP-1, while semaglutide provides the familiar GLP-1 receptor activation

compounded under Section 503A for individual prescriptions Hepatic impairment data / no controlled pharmacokinetic studies in liver disease populations Copper clearance / 85-95% of circulating copper is bound to ceruloplasmin, which is synthesized exclusively in the liver [1] Wilson disease parallel / hepatic copper accumulation can reach 250+ mcg/g dry weight in impaired biliary excretion [2] Child-Pugh A / may proceed with standard dosing and baseline copper labs Child-Pugh B / dose reduction recommended with monthly copper monitoring Child-Pugh C / use generally not recommended due to impaired biliary copper excretion Standard compounded dose / 1-2 mg subcutaneously daily or 3 times weekly Key monitoring labs / serum copper, ceruloplasmin, 24-hour urine copper, liver function tests What Is GHK-Cu and How Does It Work

General function: Involved in methyltransferase activity Specific function: Specifically methylates guanosine-4 in various tRNAs with a Gly(CCG), His or Pro signature Gene Name: TRM13 Uniprot ID: Q12383 Molecular weight: 54094.5 Reactions S-adenosyl-L-methionine + rRNA S-adenosyl-L-homocysteine + rRNA containing 2'-O-methyluridine

Improved sleep depth and onset within 5-10 days, measurable telomere lengthening after 2-3 months, increased energy, better stress resilience